Targeting weight loss and blood glucose control with oral sodium butyrate in overweight/obese adults with and without type 2 diabetes: A proof-of-concept randomized controlled trial - PubMed

4 hours ago

Oral sodium butyrate (NaBut) supplementation was tested in a 12-week randomized controlled trial involving 46 overweight/obese adults, with or without type 2 diabetes (T2D), combined with a hypoenergetic diet.
In participants without T2D, NaBut led to significantly greater weight loss (-7.0 kg) compared to placebo (-3.2 kg), and increased serum butyrate levels were linked to weight change.
In participants with T2D, NaBut did not significantly affect weight loss but reduced plasma triglycerides and improved time-in-tight-range glucose control by 9%, independent of weight change.
The study suggests NaBut may support weight loss in obese individuals without diabetes and improve metabolic markers like triglycerides and glucose control in those with T2D.

Hasty Briefsbeta